• DOI:10.1101/cshperspect.a006213
• Corpus ID: 13958626

Brain imaging in Alzheimer disease.

@article{Johnson2012BrainII,
  title={Brain imaging in Alzheimer disease.},
  author={Keith A. Johnson and Nick C Fox and Reisa A. Sperling and William E. Klunk},
  journal={Cold Spring Harbor perspectives in medicine},
  year={2012},
  volume={2 4},
  pages={
          a006213
        }
}

• Keith A. Johnson, Nick C Fox, +1 author W. Klunk
• Published 1 April 2012
• Medicine
• Cold Spring Harbor perspectives in medicine

Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past four decades. Initially, computed tomography (CT) and then magnetic resonance imaging (MRI) were used diagnostically to rule out other causes of dementia. More recently, a variety of imaging modalities including structural and functional MRI and positron emission tomography (PET) studies of cerebral metabolism with fluoro-deoxy-d-glucose (FDG) and amyloid tracers such as Pittsburgh Compound-B (PiB) have shown characteristic changes in the brains of patients with AD, and in prodromal and even presymptomatic states that can help rule-in the AD pathophysiological process. No one imaging modality can serve all purposes as each have unique strengths and weaknesses. These modalities and their particular utilities are discussed in this article. The challenge for the future will be to combine imaging biomarkers to most efficiently facilitate diagnosis, disease staging, and, most importantly, development of effective disease-modifying therapies.